A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
This study tests a targeted cancer medicine called talazoparib in adults with advanced solid tumors. Researchers want to see if this medicine works for tumors that have specific changes in genes responsible for repairing DNA.
Adults with advanced solid tumors who have specific genetic changes related to DNA repair may be able to join. Your doctors will check your test results to see if your cancer has the right gene changes for this study.
Participants will take the study drug talazoparib as a pill. Throughout the study, you will have regular check-ups, imaging scans, and provide small tissue or blood samples for lab testing.
This study has locations in Florida and Maryland in the United States. Please note that this study is currently active but not looking for new participants at this time.
- 1Tests the targeted cancer medicine talazoparib
- 2Requires specific genetic changes in your tumor
- 3Involves regular check-ups and imaging scans
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.